CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility

  • Posted by: BIOCON

Biocon Limited partners with Tabuk Pharmaceuticals to commercialize its Glucagon-like peptide-1 (GLP -1) products in the Middle East region

  • Posted by: BIOCON

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

  • Posted by: BIOCON

Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan

  • Posted by: BIOCON

Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr

  • Posted by: BIOCON

Biocon Foundation and IISc organize OCTF Conference on Artificial Intelligence in Oral Cancer

  • Posted by: BIOCON

Biocon Foundation conducts awareness session in 14 Government Schools

  • Posted by: BIOCON

Biocon Limited signs exclusive licensing and supply deal for the commercialization of Liraglutide in South Korea with Handok Inc.

  • Posted by: BIOCON

Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market

  • Posted by: BIOCON

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>